Sign in to search companies, open filing PDFs, fetch uncached SEDAR+ documents, and use the
full company research view.
Ownership 2026-07-17
Stevens, Dane Nicholas bought +$93k
Insider trading – 2026-07-17
1 insider · +$93k net
News 2026-06-29
Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression
News release - English.pdf
News 2026-06-16
Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research
News release - English.pdf
News 2026-06-10
Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial
News release - English.pdf
News 2026-06-08
Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
News release - English.pdf
News 2026-06-02
Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia
News release - English.pdf
Results 2026-06-01
Interim MD&A - English.pdf
Results 2026-06-01
Interim financial statements/report – English.pdf
News 2026-05-29
Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia
News release - English.pdf
Transactions 2026-05-26 Financing
Optimi Health Corp. Completes Uplisting to Nasdaq Capital Market and Closes US$15 Million Public Offering
Material change report - English.pdf
Transactions 2026-05-26 Financing
Report of exempt distribution (45-106F1).pdf
News 2026-05-26
Optimi Health Advances Highest-Purity Natural Psilocybin Extract to Date
News release - English.pdf
Transactions 2026-05-21 Financing
Optimi Health Announces Closing of Oversubscribed US$15 Million Public Offering
News release - English.pdf
Transactions 2026-05-20 Financing
Optimi Health Announces Pricing of Oversubscribed US$15 Million Public Offering and Nasdaq Uplisting
News release - English.pdf
Transactions 2026-04-23 Financing
Optimi Health Files LIFE Offering Document in Connection with Nasdaq Listing
News release - English.pdf
News 2026-04-20
Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products
News release - English.pdf
News 2026-02-26
Optimi Health Reports Early Clinical Rollout of Natural Psilocybin Capsules for Treatment-Resistant Depression in Australia
News release - English.pdf
News 2026-02-19
Optimi Health Completes Psilocybin Export to Australia for Treatment Resistant Depression
News release - English.pdf
Results 2026-02-19 Financials
Interim MD&A - English.pdf
Results 2026-02-19 Financials
Interim financial statements/report – English.pdf
News 2026-02-17
Optimi Health Reports First MDMA-Assisted Treatments of 2026 are Underway Across an Expanded Network of Australian Clinics
News release - English.pdf
News 2026-02-09
Optimi Health Completes MDMA Export for PTSD Treatment Under Australia's Authorised Prescriber Scheme
News release - English.pdf
Results 2026-01-29 Financials
Annual MD&A - English.pdf
Results 2026-01-29 Financials
Audited annual financial statements – English.pdf
News 2026-01-26
Optimi Health Completes First 2026 Production of MDMA and Psilocybin Capsules
News release - English.pdf
News 2026-01-22
Early warning report.pdf
Ownership 2026-01-22
Early Warning Press Release in accordance with National Instrument 62-103
Press release - English.pdf
News 2025-11-26
Optimi Health to Supply MDMA to MAPS Israel's Clinical Trial for Trauma-Related PTSD
News release - English.pdf
News 2025-10-21
News release - English.pdf
News 2025-10-06
News release - English.pdf
News 2025-09-08
News release - English.pdf
News 2025-09-03
News release - English.pdf
Results 2025-08-30 Financials
Interim MD&A - English.pdf
Results 2025-08-30 Financials
Interim financial statements/report – English.pdf
News 2025-08-20
News release - English.pdf
News 2025-08-19
Other.pdf
News 2025-08-19
Other.pdf
News 2025-08-19
Other.pdf